pgp - publications

Predict more pgp - ligand interactions now!


1. J Cereb Blood Flow Metab. 2012 May 16. doi: 10.1038/jcbfm.2012.64. [Epub ahead of
print]

No evidence for additional blood-brain barrier P-glycoprotein dysfunction in
Alzheimer's disease patients with microbleeds.

van Assema DM, Goos JD, van der Flier WM, Lubberink M, Boellaard R, Windhorst AD,
Scheltens P, Lammertsma AA, van Berckel BN.

1] Department of Nuclear Medicine and PET Research, VU University Medical Center,
Amsterdam, The Netherlands [2] Department of Neurology and Alzheimer Center, VU
University Medical Center, Amsterdam, The Netherlands.

Decreased blood-brain barrier P-glycoprotein (Pgp) function has been shown in
Alzheimer's disease (AD) patients using positron emission tomography (PET) with
the radiotracer (R)-[(11)C]verapamil. Decreased Pgp function has also been
hypothesized to promote cerebral amyloid angiopathy (CAA) development. Here, we
used PET and (R)-[(11)C]verapamil to assess Pgp function in eighteen AD patients,
of which six had microbleeds (MBs), presumably reflecting underlying CAA. No
differences were found in binding potential and nonspecific volume of
distribution of (R)-[(11)C]verapamil between patient groups. These results
provide no evidence for additional Pgp dysfunction in AD patients with
MBs.Journal of Cerebral Blood Flow & Metabolism advance online publication 16 May
2012; doi:10.1038/jcbfm.2012.64.

PMID: 22588188 [PubMed - as supplied by publisher]